{"id":3331,"date":"2024-01-23T15:20:31","date_gmt":"2024-01-23T15:20:31","guid":{"rendered":"http:\/\/rnce.inserm.fr\/les-chiffres\/"},"modified":"2024-05-30T09:23:33","modified_gmt":"2024-05-30T09:23:33","slug":"chiffres","status":"publish","type":"page","link":"https:\/\/rnce.inserm.fr\/en\/chiffres\/","title":{"rendered":"Statistics"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"3331\" class=\"elementor elementor-3331 elementor-2436\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cc5a800 e-flex e-con-boxed e-con e-child\" data-id=\"cc5a800\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d5fa547 elementor-widget elementor-widget-heading\" data-id=\"d5fa547\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.23.0 - 05-08-2024 *\/\n.elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px}<\/style><h2 class=\"elementor-heading-title elementor-size-default\">Statistiques d'incidence<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"dce-fix-background-loop elementor-element elementor-element-f733185 elementor-widget elementor-widget-dce-acf-repeater-v2\" data-id=\"f733185\" data-element_type=\"widget\" data-settings=\"{&quot;dce_acf_repeater_format&quot;:&quot;accordion&quot;,&quot;dce_acf_repeater_accordion_start&quot;:&quot;none&quot;,&quot;accordion_speed&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:300,&quot;sizes&quot;:[]}}\" data-widget_type=\"dce-acf-repeater-v2.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<div class=\"dce-acf-repeater\">\t\t\t\t\t<ul class=\"accordion\">\n\t\t\t\t\t\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-up\"><\/i><\/span>\n\t\t<span class=\"accordion-title\">\n\t\t\tNombre de cas annuel moyen (N), taux d'incidence annuel brut, standardis\u00e9 et cumul\u00e9 \u00e0 18 ans en cas par million, et sex-ratio des cancers de l'enfant en France m\u00e9tropolitaine (2014-2020*)\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-1bd15b1\"><table><thead><th><\/th><th>N_annuel<\/th><th>Brut<\/th><th>Standardise<\/th><th>cumule<\/th><th>Sex_ratio<\/th><\/thead><tbody><tr><td>I. Leuc\u00e9mies, syndromes my\u00e9loprolif\u00e9ratifs et my\u00e9lodysplasiques<\/td><td>579<\/td><td>41,2<\/td><td>42,3<\/td><td>777,6<\/td><td>1,2<\/td><\/tr><tr><td>I.a Leuc\u00e9mies lympho\u00efdes<\/td><td>447<\/td><td>31,8<\/td><td>32,6<\/td><td>597,5<\/td><td>1,3<\/td><\/tr><tr><td>I.b Leuc\u00e9mies aigu\u00ebs my\u00e9lo\u00efdes<\/td><td>90<\/td><td>6,4<\/td><td>6,6<\/td><td>121,9<\/td><td>1<\/td><\/tr><tr><td>I.c Syndromes my\u00e9loprolif\u00e9ratifs chroniques<\/td><td>16<\/td><td>1,1<\/td><td>1,2<\/td><td>23,1<\/td><td>1<\/td><\/tr><tr><td>I.d Syndromes my\u00e9lodysplasiques et autres syndromes my\u00e9loprolif\u00e9ratifs<\/td><td>18<\/td><td>1,3<\/td><td>1,3<\/td><td>24,1<\/td><td>1,4<\/td><\/tr><tr><td>I.e Leuc\u00e9mies sans autres indications<\/td><td>8<\/td><td>0,6<\/td><td>0,6<\/td><td>11,5<\/td><td>1,5<\/td><\/tr><tr><td>II. Lymphomes et n\u00e9oplasmes r\u00e9ticulo-endoth\u00e9liaux<\/td><td>329<\/td><td>23,4<\/td><td>24,4<\/td><td>468,2<\/td><td>1,4<\/td><\/tr><tr><td>II.a Lymphomes de Hodgkin<\/td><td>191<\/td><td>13,6<\/td><td>14,6<\/td><td>280,2<\/td><td>1,1<\/td><\/tr><tr><td>II.b Lymphomes non hodgkiniens (sauf lymphomes de Burkitt)<\/td><td>79<\/td><td>5,6<\/td><td>5,7<\/td><td>110<\/td><td>1,6<\/td><\/tr><tr><td>II.c Lymphomes de Burkitt<\/td><td>50<\/td><td>3,6<\/td><td>3,4<\/td><td>65,8<\/td><td>4,9<\/td><\/tr><tr><td>II.d N\u00e9oplasmes r\u00e9ticulo-endoth\u00e9liaux<\/td><td>7<\/td><td>0,5<\/td><td>0,6<\/td><td>10<\/td><td>0,9<\/td><\/tr><tr><td>II.e Lymphomes sans autres indications<\/td><td>2<\/td><td>0,1<\/td><td>0,1<\/td><td>2,6<\/td><td>0,2<\/td><\/tr><tr><td>III. Tumeurs du syst\u00e8me nerveux central et diverses tumeurs intracr\u00e2niennes et spinales<\/td><td>560<\/td><td>39,8<\/td><td>39,8<\/td><td>750<\/td><td>1,1<\/td><\/tr><tr><td>III.a \u00c9pendymomes et tumeurs du plexus choro\u00efde<\/td><td>46<\/td><td>3,3<\/td><td>3,5<\/td><td>63<\/td><td>1,3<\/td><\/tr><tr><td>III.b Astrocytomes<\/td><td>201<\/td><td>14,3<\/td><td>14,3<\/td><td>268,4<\/td><td>1<\/td><\/tr><tr><td>III.c Tumeurs embryonnaires du syst\u00e8me nerveux central<\/td><td>94<\/td><td>6,7<\/td><td>6,7<\/td><td>124,4<\/td><td>1,4<\/td><\/tr><tr><td>III.d Autres gliomes<\/td><td>83<\/td><td>5,9<\/td><td>5,7<\/td><td>109,7<\/td><td>1<\/td><\/tr><tr><td>III.e Autres tumeurs du syst\u00e8me nerveux central<\/td><td>127<\/td><td>9<\/td><td>8,9<\/td><td>173,2<\/td><td>1,1<\/td><\/tr><tr><td>III.f Tumeurs du syst\u00e8me nerveux central non pr\u00e9cis\u00e9es<\/td><td>8<\/td><td>0,6<\/td><td>0,6<\/td><td>11,2<\/td><td>1,3<\/td><\/tr><tr><td>IV. Tumeurs du syst\u00e8me nerveux sympathique<\/td><td>131<\/td><td>9,3<\/td><td>10,4<\/td><td>178,9<\/td><td>1<\/td><\/tr><tr><td>IV.a Neuroblastomes et ganglioneuroblastomes<\/td><td>128<\/td><td>9,1<\/td><td>10,1<\/td><td>173,9<\/td><td>1<\/td><\/tr><tr><td>IV.b Autres tumeurs du syst\u00e8me nerveux sympathique<\/td><td>4<\/td><td>0,3<\/td><td>0,3<\/td><td>5<\/td><td>1<\/td><\/tr><tr><td>V. R\u00e9tinoblastomes<\/td><td>50<\/td><td>3,6<\/td><td>4,1<\/td><td>68,4<\/td><td>1<\/td><\/tr><tr><td>VI. Tumeurs r\u00e9nales<\/td><td>95<\/td><td>6,8<\/td><td>7,3<\/td><td>127,6<\/td><td>0,7<\/td><\/tr><tr><td>VI.a N\u00e9phroblastomes et autres tumeurs non \u00e9pith\u00e9liales<\/td><td>89<\/td><td>6,3<\/td><td>6,8<\/td><td>118,7<\/td><td>0,7<\/td><\/tr><tr><td>VI.b Carcinomes r\u00e9naux<\/td><td>6<\/td><td>0,4<\/td><td>0,5<\/td><td>8,9<\/td><td>0,7<\/td><\/tr><tr><td>VI.c Tumeurs r\u00e9nales non pr\u00e9cis\u00e9es<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>VII. Tumeurs h\u00e9patiques<\/td><td>22<\/td><td>1,5<\/td><td>1,7<\/td><td>29,9<\/td><td>1,7<\/td><\/tr><tr><td>VII.a H\u00e9patoblastomes<\/td><td>17<\/td><td>1,2<\/td><td>1,3<\/td><td>22,4<\/td><td>1,8<\/td><\/tr><tr><td>VII.b Carcinomes h\u00e9patiques<\/td><td>5<\/td><td>0,3<\/td><td>0,4<\/td><td>7,3<\/td><td>1,3<\/td><\/tr><tr><td>VII.c Tumeurs h\u00e9patiques non pr\u00e9cis\u00e9es<\/td><td>0<\/td><td>0<\/td><td>0<\/td><td>0,2<\/td><td>0<\/td><\/tr><tr><td>VIII. Tumeurs malignes osseuses<\/td><td>130<\/td><td>9,3<\/td><td>9,2<\/td><td>180,9<\/td><td>1,2<\/td><\/tr><tr><td>VIII.a Ost\u00e9osarcomes<\/td><td>65<\/td><td>4,6<\/td><td>4,6<\/td><td>90,5<\/td><td>1,1<\/td><\/tr><tr><td>VIII.b Chondrosarcomes<\/td><td>3<\/td><td>0,2<\/td><td>0,2<\/td><td>4,6<\/td><td>0,9<\/td><\/tr><tr><td>VIII.c Tumeurs d'Ewing<\/td><td>58<\/td><td>4,1<\/td><td>4<\/td><td>79,5<\/td><td>1,5<\/td><\/tr><tr><td>VIII.d Autres tumeurs malignes osseuses<\/td><td>4<\/td><td>0,3<\/td><td>0,3<\/td><td>5,4<\/td><td>0,7<\/td><\/tr><tr><td>VIII.e Tumeurs malignes osseuses non pr\u00e9cis\u00e9es<\/td><td>1<\/td><td>0,1<\/td><td>0,1<\/td><td>1,5<\/td><td>1,9<\/td><\/tr><tr><td>IX. Sarcomes des tissus mous et extra-osseux<\/td><td>133<\/td><td>9,4<\/td><td>9,8<\/td><td>181,9<\/td><td>1,2<\/td><\/tr><tr><td>IX.a Rhabdomyosarcomes<\/td><td>70<\/td><td>5<\/td><td>5,2<\/td><td>95,2<\/td><td>1,2<\/td><\/tr><tr><td>IX.b Fibrosarcomes, tumeurs des gaines des nerfs p\u00e9riph\u00e9riques et autres tumeurs fibreuses<\/td><td>12<\/td><td>0,8<\/td><td>0,9<\/td><td>16,5<\/td><td>1,2<\/td><\/tr><tr><td>IX.c Sarcome de Kaposi<\/td><td>0<\/td><td>0<\/td><td>0<\/td><td>0,8<\/td><td>1,9<\/td><\/tr><tr><td>IX.d Autres sarcomes des tissus mous<\/td><td>40<\/td><td>2,9<\/td><td>2,9<\/td><td>55,9<\/td><td>1,2<\/td><\/tr><tr><td>IX.e Sarcomes des tissus mous non pr\u00e9cis\u00e9s<\/td><td>10<\/td><td>0,7<\/td><td>0,7<\/td><td>13,6<\/td><td>1,3<\/td><\/tr><tr><td>X. Tumeurs germinales, trophoblastiques et gonadiques<\/td><td>94<\/td><td>6,7<\/td><td>7,2<\/td><td>133,6<\/td><td>1<\/td><\/tr><tr><td>X.a Tumeurs germinales du syst\u00e8me nerveux central<\/td><td>30<\/td><td>2,1<\/td><td>2,1<\/td><td>40,5<\/td><td>2,6<\/td><\/tr><tr><td>X.b Tumeurs germinales malignes extragonadiques et extracr\u00e2niennes<\/td><td>17<\/td><td>1,2<\/td><td>1,5<\/td><td>25<\/td><td>0,6<\/td><\/tr><tr><td>X.c Tumeurs germinales malignes gonadiques<\/td><td>44<\/td><td>3,1<\/td><td>3,4<\/td><td>64,2<\/td><td>0,7<\/td><\/tr><tr><td>X.d Carcinomes gonadiques<\/td><td>2<\/td><td>0,1<\/td><td>0,1<\/td><td>2,6<\/td><td>0<\/td><\/tr><tr><td>X.e Autres tumeurs gonadiques ou non pr\u00e9cis\u00e9es<\/td><td>1<\/td><td>0,1<\/td><td>0,1<\/td><td>1,6<\/td><td>0,1<\/td><\/tr><tr><td>XI. M\u00e9lanomes malins et autres tumeurs malignes \u00e9pith\u00e9liales<\/td><td>130<\/td><td>9,2<\/td><td>10<\/td><td>190,4<\/td><td>0,6<\/td><\/tr><tr><td>XI.a Ad\u00e9nocarcinomes de la corticosurr\u00e9nale<\/td><td>5<\/td><td>0,3<\/td><td>0,4<\/td><td>6,8<\/td><td>0,7<\/td><\/tr><tr><td>XI.b Carcinomes de la thyro\u00efde<\/td><td>57<\/td><td>4,1<\/td><td>4,6<\/td><td>86,5<\/td><td>0,3<\/td><\/tr><tr><td>XI.c Carcinomes du nasopharynx<\/td><td>7<\/td><td>0,5<\/td><td>0,5<\/td><td>10,2<\/td><td>2,3<\/td><\/tr><tr><td>XI.d M\u00e9lanomes malins<\/td><td>16<\/td><td>1,1<\/td><td>1,2<\/td><td>23,1<\/td><td>0,8<\/td><\/tr><tr><td>XI.e Carcinomes cutan\u00e9s<\/td><td>5<\/td><td>0,4<\/td><td>0,4<\/td><td>7,5<\/td><td>1<\/td><\/tr><tr><td>XI.f Autres carcinomes<\/td><td>40<\/td><td>2,8<\/td><td>2,9<\/td><td>56,3<\/td><td>0,8<\/td><\/tr><tr><td>XII. Autres tumeurs malignes<\/td><td>7<\/td><td>0,5<\/td><td>0,6<\/td><td>10,2<\/td><td>1<\/td><\/tr><tr><td>XII.a Autres tumeurs malignes pr\u00e9cis\u00e9es<\/td><td>6<\/td><td>0,5<\/td><td>0,5<\/td><td>8,8<\/td><td>0,9<\/td><\/tr><tr><td>XII.b Autres tumeurs malignes non pr\u00e9cis\u00e9es<\/td><td>1<\/td><td>0,1<\/td><td>0<\/td><td>0,9<\/td><td>1,9<\/td><\/tr><tr><td>Total<\/td><td>2260<\/td><td>160,7<\/td><td>166,6<\/td><td>3093,9<\/td><td>1,1<\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li>\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-up\"><\/i><\/span>\n\t\t<span class=\"accordion-title accordion-title\">\n\t\t\tNombre de cas annuel moyen (N), taux d'incidence annuel brut, standardis\u00e9 et cumul\u00e9 \u00e0 15 ans en cas par million, et sex-ratio des cancers de l'enfant en France m\u00e9tropolitaine (2014-2020*)\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-1bd15b1\"><table><thead><th><\/th><th>N_annuel<\/th><th>Brut<\/th><th>Standardise<\/th><th>cumule<\/th><th>Sex_ratio<\/th><\/thead><tbody><tr><td>I. Leuc\u00e9mies, syndromes my\u00e9loprolif\u00e9ratifs et my\u00e9lodysplasiques<\/td><td>511<\/td><td>43,8<\/td><td>46,4<\/td><td>664,9<\/td><td>1,2<\/td><\/tr><tr><td>I.a Leuc\u00e9mies lympho\u00efdes<\/td><td>404<\/td><td>34,6<\/td><td>36,8<\/td><td>525,6<\/td><td>1,2<\/td><\/tr><tr><td>I.b Leuc\u00e9mies aigu\u00ebs my\u00e9lo\u00efdes<\/td><td>75<\/td><td>6,4<\/td><td>6,7<\/td><td>97,1<\/td><td>1,1<\/td><\/tr><tr><td>I.c Syndromes my\u00e9loprolif\u00e9ratifs chroniques<\/td><td>9<\/td><td>0,8<\/td><td>0,7<\/td><td>11,9<\/td><td>1<\/td><\/tr><tr><td>I.d Syndromes my\u00e9lodysplasiques et autres syndromes my\u00e9loprolif\u00e9ratifs<\/td><td>16<\/td><td>1,4<\/td><td>1,6<\/td><td>21,7<\/td><td>1,4<\/td><\/tr><tr><td>I.e Leuc\u00e9mies sans autres indications<\/td><td>7<\/td><td>0,6<\/td><td>0,6<\/td><td>8,7<\/td><td>1,3<\/td><\/tr><tr><td>II. Lymphomes et n\u00e9oplasmes r\u00e9ticulo-endoth\u00e9liaux<\/td><td>200<\/td><td>17,2<\/td><td>15,8<\/td><td>253,1<\/td><td>1,8<\/td><\/tr><tr><td>II.a Lymphomes de Hodgkin<\/td><td>92<\/td><td>7,9<\/td><td>6,9<\/td><td>115,4<\/td><td>1,3<\/td><\/tr><tr><td>II.b Lymphomes non hodgkiniens (sauf lymphomes de Burkitt)<\/td><td>55<\/td><td>4,7<\/td><td>4,4<\/td><td>69,2<\/td><td>1,7<\/td><\/tr><tr><td>II.c Lymphomes de Burkitt<\/td><td>46<\/td><td>4<\/td><td>3,9<\/td><td>59<\/td><td>4,9<\/td><\/tr><tr><td>II.d N\u00e9oplasmes r\u00e9ticulo-endoth\u00e9liaux<\/td><td>6<\/td><td>0,6<\/td><td>0,6<\/td><td>8,4<\/td><td>0,8<\/td><\/tr><tr><td>II.e Lymphomes sans autres indications<\/td><td>1<\/td><td>0,1<\/td><td>0,1<\/td><td>1<\/td><td>0,5<\/td><\/tr><tr><td>III. Tumeurs du syst\u00e8me nerveux central et diverses tumeurs intracr\u00e2niennes et spinales<\/td><td>485<\/td><td>41,6<\/td><td>42,3<\/td><td>625,3<\/td><td>1,1<\/td><\/tr><tr><td>III.a \u00c9pendymomes et tumeurs du plexus choro\u00efde<\/td><td>40<\/td><td>3,5<\/td><td>3,8<\/td><td>53<\/td><td>1,3<\/td><\/tr><tr><td>III.b Astrocytomes<\/td><td>178<\/td><td>15,2<\/td><td>15,7<\/td><td>229,6<\/td><td>0,9<\/td><\/tr><tr><td>III.c Tumeurs embryonnaires du syst\u00e8me nerveux central<\/td><td>89<\/td><td>7,6<\/td><td>8<\/td><td>114,8<\/td><td>1,4<\/td><\/tr><tr><td>III.d Autres gliomes<\/td><td>73<\/td><td>6,3<\/td><td>6,2<\/td><td>93,3<\/td><td>1<\/td><\/tr><tr><td>III.e Autres tumeurs du syst\u00e8me nerveux central<\/td><td>98<\/td><td>8,4<\/td><td>8<\/td><td>124,8<\/td><td>1,1<\/td><\/tr><tr><td>III.f Tumeurs du syst\u00e8me nerveux central non pr\u00e9cis\u00e9es<\/td><td>7<\/td><td>0,6<\/td><td>0,7<\/td><td>9,6<\/td><td>1,3<\/td><\/tr><tr><td>IV. Tumeurs du syst\u00e8me nerveux sympathique<\/td><td>129<\/td><td>11,1<\/td><td>13,1<\/td><td>175,3<\/td><td>1<\/td><\/tr><tr><td>IV.a Neuroblastomes et ganglioneuroblastomes<\/td><td>126<\/td><td>10,8<\/td><td>12,9<\/td><td>171,9<\/td><td>1<\/td><\/tr><tr><td>IV.b Autres tumeurs du syst\u00e8me nerveux sympathique<\/td><td>3<\/td><td>0,2<\/td><td>0,2<\/td><td>3,4<\/td><td>0,8<\/td><\/tr><tr><td>V. R\u00e9tinoblastomes<\/td><td>50<\/td><td>4,3<\/td><td>5,2<\/td><td>68,4<\/td><td>1<\/td><\/tr><tr><td>VI. Tumeurs r\u00e9nales<\/td><td>92<\/td><td>7,9<\/td><td>9<\/td><td>122,4<\/td><td>0,7<\/td><\/tr><tr><td>VI.a N\u00e9phroblastomes et autres tumeurs non \u00e9pith\u00e9liales<\/td><td>88<\/td><td>7,5<\/td><td>8,7<\/td><td>117,1<\/td><td>0,7<\/td><\/tr><tr><td>VI.b Carcinomes r\u00e9naux<\/td><td>4<\/td><td>0,3<\/td><td>0,3<\/td><td>4,9<\/td><td>0,8<\/td><\/tr><tr><td>VI.c Tumeurs r\u00e9nales non pr\u00e9cis\u00e9es<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>VII. Tumeurs h\u00e9patiques<\/td><td>19<\/td><td>1,6<\/td><td>1,9<\/td><td>25,9<\/td><td>1,8<\/td><\/tr><tr><td>VII.a H\u00e9patoblastomes<\/td><td>17<\/td><td>1,4<\/td><td>1,7<\/td><td>22<\/td><td>1,8<\/td><\/tr><tr><td>VII.b Carcinomes h\u00e9patiques<\/td><td>2<\/td><td>0,2<\/td><td>0,2<\/td><td>3,3<\/td><td>1,8<\/td><\/tr><tr><td>VII.c Tumeurs h\u00e9patiques non pr\u00e9cis\u00e9es<\/td><td>0<\/td><td>0<\/td><td>0<\/td><td>0,2<\/td><td>0<\/td><\/tr><tr><td>VIII. Tumeurs malignes osseuses<\/td><td>89<\/td><td>7,6<\/td><td>6,8<\/td><td>111,7<\/td><td>1,1<\/td><\/tr><tr><td>VIII.a Ost\u00e9osarcomes<\/td><td>43<\/td><td>3,7<\/td><td>3,2<\/td><td>53,7<\/td><td>0,9<\/td><\/tr><tr><td>VIII.b Chondrosarcomes<\/td><td>2<\/td><td>0,1<\/td><td>0,1<\/td><td>2,2<\/td><td>0,8<\/td><\/tr><tr><td>VIII.c Tumeurs d'Ewing<\/td><td>41<\/td><td>3,5<\/td><td>3,2<\/td><td>52,3<\/td><td>1,5<\/td><\/tr><tr><td>VIII.d Autres tumeurs malignes osseuses<\/td><td>3<\/td><td>0,2<\/td><td>0,2<\/td><td>3<\/td><td>1<\/td><\/tr><tr><td>VIII.e Tumeurs malignes osseuses non pr\u00e9cis\u00e9es<\/td><td>1<\/td><td>0,1<\/td><td>0,1<\/td><td>1,1<\/td><td>1,4<\/td><\/tr><tr><td>IX. Sarcomes des tissus mous et extra-osseux<\/td><td>106<\/td><td>9,1<\/td><td>9,4<\/td><td>137,9<\/td><td>1,3<\/td><\/tr><tr><td>IX.a Rhabdomyosarcomes<\/td><td>59<\/td><td>5<\/td><td>5,4<\/td><td>76,8<\/td><td>1,2<\/td><\/tr><tr><td>IX.b Fibrosarcomes, tumeurs des gaines des nerfs p\u00e9riph\u00e9riques et autres tumeurs fibreuses<\/td><td>9<\/td><td>0,7<\/td><td>0,8<\/td><td>11,3<\/td><td>1,4<\/td><\/tr><tr><td>IX.c Sarcome de Kaposi<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>IX.d Autres sarcomes des tissus mous<\/td><td>31<\/td><td>2,6<\/td><td>2,6<\/td><td>39,5<\/td><td>1,4<\/td><\/tr><tr><td>IX.e Sarcomes des tissus mous non pr\u00e9cis\u00e9s<\/td><td>8<\/td><td>0,7<\/td><td>0,7<\/td><td>10,4<\/td><td>1,3<\/td><\/tr><tr><td>X. Tumeurs germinales, trophoblastiques et gonadiques<\/td><td>64<\/td><td>5,4<\/td><td>5,5<\/td><td>82,8<\/td><td>0,7<\/td><\/tr><tr><td>X.a Tumeurs germinales du syst\u00e8me nerveux central<\/td><td>24<\/td><td>2<\/td><td>1,9<\/td><td>30,5<\/td><td>2,3<\/td><\/tr><tr><td>X.b Tumeurs germinales malignes extragonadiques et extracr\u00e2niennes<\/td><td>16<\/td><td>1,3<\/td><td>1,7<\/td><td>21,8<\/td><td>0,5<\/td><\/tr><tr><td>X.c Tumeurs germinales malignes gonadiques<\/td><td>22<\/td><td>1,9<\/td><td>1,8<\/td><td>28,2<\/td><td>0,3<\/td><\/tr><tr><td>X.d Carcinomes gonadiques<\/td><td>1<\/td><td>0,1<\/td><td>0,1<\/td><td>1<\/td><td>0<\/td><\/tr><tr><td>X.e Autres tumeurs gonadiques ou non pr\u00e9cis\u00e9es<\/td><td>1<\/td><td>0,1<\/td><td>0,1<\/td><td>1,2<\/td><td>0,2<\/td><\/tr><tr><td>XI. M\u00e9lanomes malins et autres tumeurs malignes \u00e9pith\u00e9liales<\/td><td>65<\/td><td>5,6<\/td><td>5<\/td><td>82<\/td><td>0,7<\/td><\/tr><tr><td>XI.a Ad\u00e9nocarcinomes de la corticosurr\u00e9nale<\/td><td>4<\/td><td>0,3<\/td><td>0,4<\/td><td>5,2<\/td><td>0,7<\/td><\/tr><tr><td>XI.b Carcinomes de la thyro\u00efde<\/td><td>23<\/td><td>2<\/td><td>1,8<\/td><td>29,3<\/td><td>0,4<\/td><\/tr><tr><td>XI.c Carcinomes du nasopharynx<\/td><td>4<\/td><td>0,3<\/td><td>0,3<\/td><td>5<\/td><td>3,2<\/td><\/tr><tr><td>XI.d M\u00e9lanomes malins<\/td><td>8<\/td><td>0,7<\/td><td>0,7<\/td><td>10,3<\/td><td>0,8<\/td><\/tr><tr><td>XI.e Carcinomes cutan\u00e9s<\/td><td>3<\/td><td>0,3<\/td><td>0,3<\/td><td>4,3<\/td><td>0,7<\/td><\/tr><tr><td>XI.f Autres carcinomes<\/td><td>22<\/td><td>1,9<\/td><td>1,6<\/td><td>27,5<\/td><td>0,8<\/td><\/tr><tr><td>XII. Autres tumeurs malignes<\/td><td>6<\/td><td>0,5<\/td><td>0,6<\/td><td>8,2<\/td><td>1<\/td><\/tr><tr><td>XII.a Autres tumeurs malignes pr\u00e9cis\u00e9es<\/td><td>6<\/td><td>0,5<\/td><td>0,5<\/td><td>7,2<\/td><td>1<\/td><\/tr><tr><td>XII.b Autres tumeurs malignes non pr\u00e9cis\u00e9es<\/td><td>1<\/td><td>0<\/td><td>0<\/td><td>0,5<\/td><td>1<\/td><\/tr><tr><td>Total<\/td><td>1817<\/td><td>155,7<\/td><td>161,2<\/td><td>2355,5<\/td><td>1,1<\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li>\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-up\"><\/i><\/span>\n\t\t<span class=\"accordion-title accordion-title accordion-title\">\n\t\t\tNombre de cas annuel moyen (N), taux d'incidence annuel sp\u00e9cifique en cas par million d'enfants (TI), par tranche d'\u00e2ge des cancers de l'enfant en France m\u00e9tropolitaine (2014-2020*)\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-1bd15b1\"><table><thead><th><\/th><th>< 1 an<\/th><th><\/th><th>1-4 ans<\/th><th><\/th><th>5-9 ans<\/th><th><\/th><th>10-14 ans <\/th><th><\/th><th>15-17 ans<\/th><th><\/th><\/thead><tbody><tr><td><\/td><td>N<\/td><td>TI<\/td><td>N<\/td><td>TI<\/td><td>N<\/td><td>TI<\/td><td>N<\/td><td>TI<\/td><td>N<\/td><td>TI<\/td><\/tr><tr><td>I. Leuc\u00e9mies, syndromes my\u00e9loprolif\u00e9ratifs et my\u00e9lodysplasiques<\/td><td>28<\/td><td>39,5<\/td><td>221<\/td><td>74,4<\/td><td>151<\/td><td>37,9<\/td><td>111<\/td><td>27,7<\/td><td>68<\/td><td>28,2<\/td><\/tr><tr><td>I.a Leuc\u00e9mies lympho\u00efdes<\/td><td>11<\/td><td>15,2<\/td><td>192<\/td><td>64,5<\/td><td>123<\/td><td>30,9<\/td><td>79<\/td><td>19,6<\/td><td>43<\/td><td>18<\/td><\/tr><tr><td>I.b Leuc\u00e9mies aigu\u00ebs my\u00e9lo\u00efdes<\/td><td>10<\/td><td>14,6<\/td><td>22<\/td><td>7,5<\/td><td>20<\/td><td>5<\/td><td>22<\/td><td>5,5<\/td><td>15<\/td><td>6,2<\/td><\/tr><tr><td>II. Lymphomes et n\u00e9oplasmes r\u00e9ticulo-endoth\u00e9liaux<\/td><td>3<\/td><td>4,9<\/td><td>22<\/td><td>7,3<\/td><td>59<\/td><td>14,8<\/td><td>116<\/td><td>29<\/td><td>129<\/td><td>53,8<\/td><\/tr><tr><td>II.a Lymphomes de Hodgkin<\/td><td>0<\/td><td>0<\/td><td>2<\/td><td>0,6<\/td><td>17<\/td><td>4,4<\/td><td>73<\/td><td>18,2<\/td><td>99<\/td><td>41,2<\/td><\/tr><tr><td>II.b Lymphomes non hodgkiniens (sauf lymphomes de Burkitt)<\/td><td>1<\/td><td>1,2<\/td><td>7<\/td><td>2,5<\/td><td>17<\/td><td>4,4<\/td><td>29<\/td><td>7,2<\/td><td>24<\/td><td>10,2<\/td><\/tr><tr><td>II.c Lymphomes de Burkitt<\/td><td>0<\/td><td>0,2<\/td><td>10<\/td><td>3,2<\/td><td>24<\/td><td>6<\/td><td>13<\/td><td>3,2<\/td><td>4<\/td><td>1,7<\/td><\/tr><tr><td>III. Tumeurs du syst\u00e8me nerveux central et diverses tumeurs intracr\u00e2niennes et spinales<\/td><td>25<\/td><td>35,6<\/td><td>151<\/td><td>50,6<\/td><td>168<\/td><td>42,2<\/td><td>142<\/td><td>35,3<\/td><td>75<\/td><td>31,2<\/td><\/tr><tr><td>III.a \u00c9pendymomes et tumeurs du plexus choro\u00efde<\/td><td>4<\/td><td>6,3<\/td><td>19<\/td><td>6,3<\/td><td>10<\/td><td>2,4<\/td><td>7<\/td><td>1,9<\/td><td>6<\/td><td>2,5<\/td><\/tr><tr><td>III.b Astrocytomes<\/td><td>8<\/td><td>11,3<\/td><td>65<\/td><td>21,7<\/td><td>58<\/td><td>14,5<\/td><td>47<\/td><td>11,8<\/td><td>23<\/td><td>9,7<\/td><\/tr><tr><td>III.c Tumeurs embryonnaires du syst\u00e8me nerveux central<\/td><td>6<\/td><td>8,7<\/td><td>34<\/td><td>11,4<\/td><td>32<\/td><td>8<\/td><td>17<\/td><td>4,1<\/td><td>6<\/td><td>2,4<\/td><\/tr><tr><td>III.d Autres gliomes<\/td><td>3<\/td><td>3,6<\/td><td>16<\/td><td>5,3<\/td><td>32<\/td><td>8,1<\/td><td>22<\/td><td>5,6<\/td><td>10<\/td><td>4,1<\/td><\/tr><tr><td>III.e Autres tumeurs du syst\u00e8me nerveux central<\/td><td>3<\/td><td>4,3<\/td><td>15<\/td><td>5<\/td><td>34<\/td><td>8,6<\/td><td>46<\/td><td>11,5<\/td><td>29<\/td><td>12,1<\/td><\/tr><tr><td>IV. Tumeurs du syst\u00e8me nerveux sympathique<\/td><td>47<\/td><td>66<\/td><td>60<\/td><td>20,2<\/td><td>17<\/td><td>4,2<\/td><td>6<\/td><td>1,5<\/td><td>2<\/td><td>0,9<\/td><\/tr><tr><td>IV.a Neuroblastomes et ganglioneuroblastomes<\/td><td>47<\/td><td>66<\/td><td>60<\/td><td>20,1<\/td><td>16<\/td><td>4,1<\/td><td>4<\/td><td>1<\/td><td>1<\/td><td>0,5<\/td><\/tr><tr><td>V. R\u00e9tinoblastomes<\/td><td>21<\/td><td>29,3<\/td><td>27<\/td><td>8,9<\/td><td>3<\/td><td>0,7<\/td><td>0<\/td><td>0<\/td><td>0<\/td><td>0<\/td><\/tr><tr><td>VI. Tumeurs r\u00e9nales<\/td><td>12<\/td><td>17<\/td><td>55<\/td><td>18,6<\/td><td>19<\/td><td>4,7<\/td><td>6<\/td><td>1,5<\/td><td>3<\/td><td>1,3<\/td><\/tr><tr><td>VI.a N\u00e9phroblastomes et autres tumeurs non \u00e9pith\u00e9liales<\/td><td>12<\/td><td>17<\/td><td>55<\/td><td>18,4<\/td><td>18<\/td><td>4,5<\/td><td>3<\/td><td>0,8<\/td><td>1<\/td><td>0,4<\/td><\/tr><tr><td>VII. Tumeurs h\u00e9patiques<\/td><td>6<\/td><td>7,9<\/td><td>9<\/td><td>3<\/td><td>3<\/td><td>0,7<\/td><td>2<\/td><td>0,5<\/td><td>2<\/td><td>1<\/td><\/tr><tr><td>VII.a H\u00e9patoblastomes<\/td><td>5<\/td><td>7,3<\/td><td>8<\/td><td>2,8<\/td><td>2<\/td><td>0,6<\/td><td>1<\/td><td>0,1<\/td><td>0<\/td><td>0,1<\/td><\/tr><tr><td>VIII. Tumeurs malignes osseuses<\/td><td>1<\/td><td>1,6<\/td><td>4<\/td><td>1,4<\/td><td>23<\/td><td>5,8<\/td><td>61<\/td><td>15,1<\/td><td>41<\/td><td>17,3<\/td><\/tr><tr><td>VIII.a Ost\u00e9osarcomes<\/td><td>0<\/td><td>0<\/td><td>1<\/td><td>0,3<\/td><td>9<\/td><td>2,4<\/td><td>32<\/td><td>8,1<\/td><td>22<\/td><td>9,2<\/td><\/tr><tr><td>VIII.c Tumeurs d'Ewing<\/td><td>1<\/td><td>1,2<\/td><td>3<\/td><td>0,9<\/td><td>12<\/td><td>3,1<\/td><td>26<\/td><td>6,4<\/td><td>16<\/td><td>6,8<\/td><\/tr><tr><td>IX. Sarcomes des tissus mous et extra-osseux<\/td><td>11<\/td><td>15,4<\/td><td>33<\/td><td>11<\/td><td>30<\/td><td>7,5<\/td><td>33<\/td><td>8,2<\/td><td>26<\/td><td>11<\/td><\/tr><tr><td>IX.a Rhabdomyosarcomes<\/td><td>4<\/td><td>6,1<\/td><td>25<\/td><td>8,3<\/td><td>18<\/td><td>4,6<\/td><td>12<\/td><td>2,9<\/td><td>11<\/td><td>4,6<\/td><\/tr><tr><td>IX.b Fibrosarcomes, tumeurs des gaines des nerfs p\u00e9riph\u00e9riques et autres tumeurs fibreuses<\/td><td>3<\/td><td>3,6<\/td><td>1<\/td><td>0,3<\/td><td>2<\/td><td>0,5<\/td><td>3<\/td><td>0,8<\/td><td>3<\/td><td>1,3<\/td><\/tr><tr><td>IX.d Autres sarcomes des tissus mous<\/td><td>3<\/td><td>4,9<\/td><td>6<\/td><td>1,9<\/td><td>7<\/td><td>1,8<\/td><td>14<\/td><td>3,6<\/td><td>10<\/td><td>4,1<\/td><\/tr><tr><td>IX.e Sarcomes des tissus mous non pr\u00e9cis\u00e9s<\/td><td>1<\/td><td>0,8<\/td><td>1<\/td><td>0,4<\/td><td>2<\/td><td>0,6<\/td><td>4<\/td><td>1<\/td><td>2<\/td><td>0,8<\/td><\/tr><tr><td>X. Tumeurs germinales, trophoblastiques et gonadiques<\/td><td>14<\/td><td>19,6<\/td><td>10<\/td><td>3,3<\/td><td>12<\/td><td>3,1<\/td><td>28<\/td><td>6,9<\/td><td>30<\/td><td>12,7<\/td><\/tr><tr><td>X.a Tumeurs germinales du syst\u00e8me nerveux central<\/td><td>1<\/td><td>1,6<\/td><td>3<\/td><td>1,1<\/td><td>7<\/td><td>1,8<\/td><td>13<\/td><td>3,1<\/td><td>6<\/td><td>2,5<\/td><\/tr><tr><td>X.b Tumeurs germinales malignes extragonadiques et extracr\u00e2niennes<\/td><td>11<\/td><td>15,6<\/td><td>4<\/td><td>1,3<\/td><td>0<\/td><td>0,1<\/td><td>0<\/td><td>0,1<\/td><td>2<\/td><td>0,8<\/td><\/tr><tr><td>X.c Tumeurs germinales malignes gonadiques<\/td><td>2<\/td><td>2,2<\/td><td>3<\/td><td>1<\/td><td>5<\/td><td>1,2<\/td><td>13<\/td><td>3,2<\/td><td>21<\/td><td>9<\/td><\/tr><tr><td>XI. M\u00e9lanomes malins et autres tumeurs malignes \u00e9pith\u00e9liales<\/td><td>1<\/td><td>1,4<\/td><td>6<\/td><td>1,9<\/td><td>14<\/td><td>3,6<\/td><td>44<\/td><td>11<\/td><td>65<\/td><td>27,1<\/td><\/tr><tr><td>XI.b Carcinomes de la thyro\u00efde<\/td><td>0<\/td><td>0,6<\/td><td>1<\/td><td>0,3<\/td><td>4<\/td><td>1,1<\/td><td>18<\/td><td>4,4<\/td><td>34<\/td><td>14,3<\/td><\/tr><tr><td>XI.d M\u00e9lanomes malins<\/td><td>0<\/td><td>0<\/td><td>2<\/td><td>0,7<\/td><td>3<\/td><td>0,6<\/td><td>4<\/td><td>0,9<\/td><td>8<\/td><td>3,2<\/td><\/tr><tr><td>XII. Autres tumeurs malignes<\/td><td>2<\/td><td>2,2<\/td><td>3<\/td><td>1<\/td><td>0<\/td><td>0,1<\/td><td>1<\/td><td>0,3<\/td><td>1<\/td><td>0,5<\/td><\/tr><tr><td>Total<\/td><td>170<\/td><td>240,4<\/td><td>600<\/td><td>201,6<\/td><td>498<\/td><td>125,1<\/td><td>550<\/td><td>137,2<\/td><td>443<\/td><td>185,1<\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li>\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-up\"><\/i><\/span>\n\t\t<span class=\"accordion-title accordion-title accordion-title accordion-title\">\n\t\t\tVariation temporelle de l'incidence des cancers de l'enfant en France m\u00e9tropolitaine sur la p\u00e9riode 2000-2016\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-1bd15b1\"><table><thead><th>Groupes et sous-groupes diagnostiques<\/th><th>N<\/th><th>VMA (%)<\/th><th>IC95%<\/th><th>p<\/th><\/thead><tbody><tr><td>I. Leuc\u00e9mies, syndromes my\u00e9loprolif\u00e9ratifs et my\u00e9lodysplasiques<\/td><td>8503<\/td><td>0,1<\/td><td>[-0,3;0,6]<\/td><td>0,51<\/td><\/tr><tr><td>I.a Leuc\u00e9mies lympho\u00efdes<\/td><td>6678<\/td><td>0,3<\/td><td>[-0,2;0,8]<\/td><td>0,18<\/td><\/tr><tr><td>I.b Leuc\u00e9mies aigu\u00ebs my\u00e9lo\u00efdes<\/td><td>1231<\/td><td>-0,5<\/td><td>[-1,6;0,7]<\/td><td>0,43<\/td><\/tr><tr><td>II. Lymphomes et n\u00e9oplasmes r\u00e9ticulo-endoth\u00e9liaux<\/td><td>3258<\/td><td>-0,4<\/td><td>[-1,1;0,3]<\/td><td>0,22<\/td><\/tr><tr><td>II.a Lymphomes de Hodgkin<\/td><td>1480<\/td><td>0,5<\/td><td>[-0,5;1,6]<\/td><td>0,34<\/td><\/tr><tr><td>II.b Lymphomes non hodgkiniens (sauf lymphomes de Burkitt)<\/td><td>983<\/td><td>-0,7<\/td><td>[-2,0;0,6]<\/td><td>0,29<\/td><\/tr><tr><td>II.c Lymphomes de Burkitt<\/td><td>788<\/td><td>-1,9<\/td><td>[-3,3;-0,5]<\/td><td>< 0,01<\/td><\/tr><tr><td>III. Tumeurs du syst\u00e8me nerveux central et diverses tumeurs intracr\u00e2niennes et spinales<\/td><td>7500<\/td><td>1,2<\/td><td>[0,7;1,7]<\/td><td>< 0,01<\/td><\/tr><tr><td>III.a \u00c9pendymomes et tumeurs du plexus choro\u00efde<\/td><td>709<\/td><td>0,5<\/td><td>[-1,0;2,0]<\/td><td>0,52<\/td><\/tr><tr><td>III.b Astrocytomes<\/td><td>2798<\/td><td>1,3<\/td><td>[0,5;2,0]<\/td><td>< 0,01<\/td><\/tr><tr><td>III.c Tumeurs embryonnaires du syst\u00e8me nerveux central<\/td><td>1422<\/td><td>0,0<\/td><td>[-1,1;1,0]<\/td><td>0,96<\/td><\/tr><tr><td>III.d Autres gliomes<\/td><td>1017<\/td><td>0,5<\/td><td>[-0,7;1,8]<\/td><td>0,40<\/td><\/tr><tr><td>III.e Autres tumeurs du syst\u00e8me nerveux central<\/td><td>1436<\/td><td>3,2<\/td><td>[2,1;4,3]<\/td><td>< 0,01<\/td><\/tr><tr><td>IV. Tumeurs du syst\u00e8me nerveux sympathique<\/td><td>2404<\/td><td>-0,5<\/td><td>[-1,3;0,3]<\/td><td>0,20<\/td><\/tr><tr><td>IV.a Neuroblastomes et ganglioneuroblastomes<\/td><td>2372<\/td><td>-0,5<\/td><td>[-1,4;0,3]<\/td><td>0,19<\/td><\/tr><tr><td>V. R\u00e9tinoblastomes<\/td><td>849<\/td><td>-0,4<\/td><td>[-1,8;1,0]<\/td><td>0,57<\/td><\/tr><tr><td>VI. Tumeurs r\u00e9nales<\/td><td>1637<\/td><td>-0,5<\/td><td>[-1,5;0,5]<\/td><td>0,29<\/td><\/tr><tr><td>VI.a N\u00e9phroblastomes et autres tumeurs non \u00e9pith\u00e9liales<\/td><td>1583<\/td><td>-0,4<\/td><td>[-1,4;0,6]<\/td><td>0,41<\/td><\/tr><tr><td>VII. Tumeurs h\u00e9patiques<\/td><td>304<\/td><td>1,8<\/td><td>[-0,5;4,2]<\/td><td>0,12<\/td><\/tr><tr><td>VII.a H\u00e9patoblastomes<\/td><td>256<\/td><td>2,0<\/td><td>[-0,6;4,6]<\/td><td>0,13<\/td><\/tr><tr><td>VIII. Tumeurs malignes osseuses<\/td><td>1422<\/td><td>0,4<\/td><td>[-0,7;1,5]<\/td><td>0,47<\/td><\/tr><tr><td>VIII.a Ost\u00e9osarcomes<\/td><td>660<\/td><td>-0,2<\/td><td>[-1,8;1,3]<\/td><td>0,78<\/td><\/tr><tr><td>VIII.c Tumeurs d'Ewing<\/td><td>657<\/td><td>1,6<\/td><td>[0,0;3,2]<\/td><td>0,05<\/td><\/tr><tr><td>IX. Sarcomes des tissus mous et extra-osseux<\/td><td>1882<\/td><td>-0,1<\/td><td>[-1,1;0,8]<\/td><td>0,76<\/td><\/tr><tr><td>IX.a Rhabdomyosarcomes<\/td><td>1019<\/td><td>0,0<\/td><td>[-1,3;1,2]<\/td><td>0,94<\/td><\/tr><tr><td>IX.b Fibrosarcomes, tumeurs des gaines des nerfs p\u00e9riph\u00e9riques et autres tumeurs fibreuses<\/td><td>139<\/td><td>0,7<\/td><td>[-2,6;4,2]<\/td><td>0,68<\/td><\/tr><tr><td>IX.d Autres sarcomes des tissus mous<\/td><td>579<\/td><td>-0,5<\/td><td>[-2,2;1,1]<\/td><td>0,52<\/td><\/tr><tr><td>IX.e Sarcomes des tissus mous non pr\u00e9cis\u00e9s<\/td><td>141<\/td><td>0,5<\/td><td>[-2,8;4,0]<\/td><td>0,76<\/td><\/tr><tr><td>X. Tumeurs germinales, trophoblastiques et gonadiques<\/td><td>1113<\/td><td>-0,9<\/td><td>[-2,1;0,2]<\/td><td>0,12<\/td><\/tr><tr><td>X.a Tumeurs germinales du syst\u00e8me nerveux central<\/td><td>423<\/td><td>0,0<\/td><td>[-1,9;2,0]<\/td><td>1,00<\/td><\/tr><tr><td>X.b Tumeurs germinales malignes extragonadiques et extracr\u00e2niennes<\/td><td>291<\/td><td>-2,1<\/td><td>[-4,4;0,2]<\/td><td>0,08<\/td><\/tr><tr><td>X.c Tumeurs germinales malignes gonadiques<\/td><td>369<\/td><td>-1,3<\/td><td>[-3,3;0,8]<\/td><td>0,22<\/td><\/tr><tr><td>XI. M\u00e9lanomes malins et autres tumeurs malignes \u00e9pith\u00e9liales<\/td><td>1024<\/td><td>1,4<\/td><td>[0,1;2,7]<\/td><td>0,03<\/td><\/tr><tr><td>XI.b Carcinomes de la thyro\u00efde<\/td><td>411<\/td><td>-1,3<\/td><td>[-3,3;0,6]<\/td><td>0,19<\/td><\/tr><tr><td>XI.d M\u00e9lanomes malins<\/td><td>186<\/td><td>-1,2<\/td><td>[-4,0;1,8]<\/td><td>0,44<\/td><\/tr><tr><td>XII. Autres tumeurs malignes<\/td><td>70<\/td><td>4,8<\/td><td>[-0,2;10,0]<\/td><td>0,06<\/td><\/tr><tr><td>Total sans les Histiocytoses langheransiennes<\/td><td>29966<\/td><td>0,3<\/td><td>[0,0;0,5]<\/td><td>0,03<\/td><\/tr><tr><td>Histiocytoses langheransiennes<\/td><td>118<\/td><td>-1,0<\/td><td>[-4,6;2,7]<\/td><td>0,60<\/td><\/tr><tr><td>Total avec les Histiocytoses langheransiennes<\/td><td>30084<\/td><td>0,3<\/td><td>[0,0;0,5]<\/td><td>0,03<\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li><\/ul><\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dcefb08 elementor-widget elementor-widget-heading\" data-id=\"dcefb08\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Statistiques de survie<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"dce-fix-background-loop elementor-element elementor-element-0a00871 elementor-widget elementor-widget-dce-acf-repeater-v2\" data-id=\"0a00871\" data-element_type=\"widget\" data-settings=\"{&quot;dce_acf_repeater_format&quot;:&quot;accordion&quot;,&quot;dce_acf_repeater_accordion_start&quot;:&quot;none&quot;,&quot;accordion_speed&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:300,&quot;sizes&quot;:[]}}\" data-widget_type=\"dce-acf-repeater-v2.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<div class=\"dce-acf-repeater\">\t\t\t\t\t<ul class=\"accordion\">\n\t\t\t\t\t\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-up\"><\/i><\/span>\n\t\t<span class=\"accordion-title\">\n\t\t\tEstimation des taux de survie \u00e0 1 an, 2 ans et 5 ans des cancers de l'enfant en France m\u00e9tropolitaine, par groupe diagnostique (2000-2016).\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-c6a9103\"><table><thead><th><\/th><th>Taux de survie (IC95%)<\/th><th><\/th><th><\/th><th><\/th><th><\/th><th><\/th><th><\/th><\/thead><tbody><tr><td>Groupes et sous-groupes diagnostiques<\/td><td>N<\/td><td>\u00e0 1 an<\/td><td><\/td><td>\u00e0 2 ans<\/td><td><\/td><td>\u00e0 5 ans<\/td><td><\/td><\/tr><tr><td>I. Leuc\u00e9mies, syndromes my\u00e9loprolif\u00e9ratifs et my\u00e9lodysplasiques<\/td><td>8503<\/td><td>94,1<\/td><td>[93,6-94,6]<\/td><td>90,4<\/td><td>[89,7-91,0]<\/td><td>86,1<\/td><td>[85,3-86,8]<\/td><\/tr><tr><td>I.a Leuc\u00e9mies lympho\u00efdes<\/td><td>6678<\/td><td>96,4<\/td><td>[95,9-96,8]<\/td><td>93,8<\/td><td>[93,1-94,3]<\/td><td>90,0<\/td><td>[89,3-90,7]<\/td><\/tr><tr><td>I.b Leuc\u00e9mies aigu\u00ebs my\u00e9lo\u00efdes<\/td><td>1231<\/td><td>84,6<\/td><td>[82,5-86,5]<\/td><td>76,6<\/td><td>[74,1-78,9]<\/td><td>70,2<\/td><td>[67,5-72,7]<\/td><\/tr><tr><td>II. Lymphomes et n\u00e9oplasmes r\u00e9ticulo-endoth\u00e9liaux<\/td><td>3258<\/td><td>96,9<\/td><td>[96,3-97,5]<\/td><td>95,4<\/td><td>[94,6-96,1]<\/td><td>94,3<\/td><td>[93,4-95,1]<\/td><\/tr><tr><td>II.a Lymphomes de Hodgkin<\/td><td>1480<\/td><td>99,6<\/td><td>[99,1-99,8]<\/td><td>98,8<\/td><td>[98,0-99,2]<\/td><td>97,7<\/td><td>[96,8-98,4]<\/td><\/tr><tr><td>II.b Lymphomes non hodgkiniens (sauf lymphomes de Burkitt)<\/td><td>983<\/td><td>94,6<\/td><td>[93,0-95,9]<\/td><td>91,4<\/td><td>[89,4-93,0]<\/td><td>89,5<\/td><td>[87,4-91,3]<\/td><\/tr><tr><td>II.c Lymphomes de Burkitt<\/td><td>788<\/td><td>94,9<\/td><td>[93,1-96,3]<\/td><td>94,3<\/td><td>[92,4-95,7]<\/td><td>94,0<\/td><td>[92,0-95,4]<\/td><\/tr><tr><td>III. Tumeurs du syst\u00e8me nerveux central et diverses tumeurs intracr\u00e2niennes et spinales<\/td><td>7500<\/td><td>85,7<\/td><td>[84,9-86,5]<\/td><td>79,3<\/td><td>[78,4-80,2]<\/td><td>74,4<\/td><td>[73,4-75,4]<\/td><\/tr><tr><td>III.a \u00c9pendymomes et tumeurs du plexus choro\u00efde<\/td><td>709<\/td><td>91,4<\/td><td>[89,0-93,2]<\/td><td>85,9<\/td><td>[83,1-88,2]<\/td><td>74,6<\/td><td>[71,1-77,8]<\/td><\/tr><tr><td>III.b Astrocytomes<\/td><td>2798<\/td><td>92,7<\/td><td>[91,7-93,6]<\/td><td>88,8<\/td><td>[87,6-89,9]<\/td><td>87,0<\/td><td>[85,6-88,2]<\/td><\/tr><tr><td>III.c Tumeurs embryonnaires du syst\u00e8me nerveux central<\/td><td>1422<\/td><td>75,4<\/td><td>[73,1-77,6]<\/td><td>66,0<\/td><td>[63,4-68,4]<\/td><td>55,7<\/td><td>[53,0-58,4]<\/td><\/tr><tr><td>III.d Autres gliomes<\/td><td>1017<\/td><td>62,3<\/td><td>[59,2-65,2]<\/td><td>44,8<\/td><td>[41,7-47,8]<\/td><td>38,7<\/td><td>[35,6-41,7]<\/td><\/tr><tr><td>III.e Autres tumeurs du syst\u00e8me nerveux central<\/td><td>1436<\/td><td>97,7<\/td><td>[96,8-98,4]<\/td><td>96,5<\/td><td>[95,4-97,4]<\/td><td>95,3<\/td><td>[94,1-96,3]<\/td><\/tr><tr><td>IV. Tumeurs du syst\u00e8me nerveux sympathique<\/td><td>2404<\/td><td>92,0<\/td><td>[90,8-93,0]<\/td><td>85,6<\/td><td>[84,1-86,9]<\/td><td>76,4<\/td><td>[74,6-78,1]<\/td><\/tr><tr><td>IV.a Neuroblastomes et ganglioneuroblastomes<\/td><td>2372<\/td><td>92,0<\/td><td>[90,8-93,0]<\/td><td>85,5<\/td><td>[84,0-86,9]<\/td><td>76,2<\/td><td>[74,4-77,9]<\/td><\/tr><tr><td>V. R\u00e9tinoblastomes<\/td><td>849<\/td><td>99,5<\/td><td>[98,7-99,8]<\/td><td>99,5<\/td><td>[98,7-99,8]<\/td><td>99,3<\/td><td>[98,4-99,7]<\/td><\/tr><tr><td>VI. Tumeurs r\u00e9nales<\/td><td>1637<\/td><td>96,8<\/td><td>[95,8-97,6]<\/td><td>94,5<\/td><td>[93,3-95,5]<\/td><td>92,7<\/td><td>[91,3-93,9]<\/td><\/tr><tr><td>VI.a N\u00e9phroblastomes et autres tumeurs non \u00e9pith\u00e9liales<\/td><td>1583<\/td><td>97,0<\/td><td>[96,0-97,7]<\/td><td>94,8<\/td><td>[93,6-95,8]<\/td><td>93,0<\/td><td>[91,6-94,2]<\/td><\/tr><tr><td>VII. Tumeurs h\u00e9patiques<\/td><td>304<\/td><td>90,4<\/td><td>[86,5-93,3]<\/td><td>86,5<\/td><td>[82,1-89,8]<\/td><td>83,1<\/td><td>[78,4-87,0]<\/td><\/tr><tr><td>VII.a H\u00e9patoblastomes<\/td><td>256<\/td><td>91,0<\/td><td>[86,8-93,9]<\/td><td>86,3<\/td><td>[81,4-90,0]<\/td><td>85,4<\/td><td>[80,5-89,2]<\/td><\/tr><tr><td>VIII. Tumeurs malignes osseuses<\/td><td>1422<\/td><td>94,4<\/td><td>[93,1-95,5]<\/td><td>87,0<\/td><td>[85,1-88,6]<\/td><td>74,1<\/td><td>[71,7-76,4]<\/td><\/tr><tr><td>VIII.a Ost\u00e9osarcomes<\/td><td>660<\/td><td>93,0<\/td><td>[90,8-94,7]<\/td><td>85,7<\/td><td>[82,7-88,1]<\/td><td>71,3<\/td><td>[67,5-74,7]<\/td><\/tr><tr><td>VIII.c Tumeurs d'Ewing<\/td><td>657<\/td><td>95,9<\/td><td>[94,1-97,2]<\/td><td>87,9<\/td><td>[85,2-90,2]<\/td><td>75,4<\/td><td>[71,8-78,7]<\/td><\/tr><tr><td>IX. Sarcomes des tissus mous et extra-osseux<\/td><td>1882<\/td><td>90,2<\/td><td>[88,7-91,4]<\/td><td>81,8<\/td><td>[80,0-83,5]<\/td><td>72,5<\/td><td>[70,4-74,6]<\/td><\/tr><tr><td>IX.a Rhabdomyosarcomes<\/td><td>1019<\/td><td>92,5<\/td><td>[90,7-94,0]<\/td><td>83,5<\/td><td>[81,0-85,6]<\/td><td>73,0<\/td><td>[70,1-75,7]<\/td><\/tr><tr><td>IX.b Fibrosarcomes, tumeurs des gaines des nerfs p\u00e9riph\u00e9riques et autres tumeurs fibreuses<\/td><td>139<\/td><td>92,8<\/td><td>[87,0-96,1]<\/td><td>87,1<\/td><td>[80,2-91,6]<\/td><td>81,2<\/td><td>[73,3-86,9]<\/td><\/tr><tr><td>IX.d Autres sarcomes des tissus mous<\/td><td>579<\/td><td>86,2<\/td><td>[83,1-88,7]<\/td><td>79,4<\/td><td>[75,9-82,5]<\/td><td>70,9<\/td><td>[66,9-74,5]<\/td><\/tr><tr><td>IX.e Sarcomes des tissus mous non pr\u00e9cis\u00e9s<\/td><td>141<\/td><td>86,5<\/td><td>[79,7-91,2]<\/td><td>74,4<\/td><td>[66,4-80,8]<\/td><td>66,8<\/td><td>[58,1-74,1]<\/td><\/tr><tr><td>X. Tumeurs germinales, trophoblastiques et gonadiques<\/td><td>1113<\/td><td>96,5<\/td><td>[95,2-97,4]<\/td><td>95,0<\/td><td>[93,5-96,1]<\/td><td>94,1<\/td><td>[92,5-95,3]<\/td><\/tr><tr><td>X.a Tumeurs germinales du syst\u00e8me nerveux central<\/td><td>423<\/td><td>96,6<\/td><td>[94,4-98,0]<\/td><td>95,1<\/td><td>[92,6-96,8]<\/td><td>94,3<\/td><td>[91,6-96,2]<\/td><\/tr><tr><td>X.b Tumeurs germinales malignes extragonadiques et extracr\u00e2niennes<\/td><td>291<\/td><td>93,5<\/td><td>[90,0-95,8]<\/td><td>92,1<\/td><td>[88,3-94,7]<\/td><td>90,9<\/td><td>[86,9-93,7]<\/td><\/tr><tr><td>X.c Tumeurs germinales malignes gonadiques<\/td><td>369<\/td><td>98,9<\/td><td>[97,1-99,6]<\/td><td>98,3<\/td><td>[96,4-99,3]<\/td><td>97,8<\/td><td>[95,6-98,9]<\/td><\/tr><tr><td>XI. M\u00e9lanomes malins et autres tumeurs malignes \u00e9pith\u00e9liales<\/td><td>1024<\/td><td>96,5<\/td><td>[95,1-97,5]<\/td><td>95,0<\/td><td>[93,4-96,2]<\/td><td>93,3<\/td><td>[91,5-94,7]<\/td><\/tr><tr><td>XI.b Carcinomes de la thyro\u00efde<\/td><td>411<\/td><td>99,3<\/td><td>[97,7-99,8]<\/td><td>99,3<\/td><td>[97,7-99,8]<\/td><td>99,0<\/td><td>[97,3-99,6]<\/td><\/tr><tr><td>XI.d M\u00e9lanomes malins<\/td><td>186<\/td><td>92,3<\/td><td>[87,4-95,4]<\/td><td>91,2<\/td><td>[86,0-94,5]<\/td><td>87,4<\/td><td>[81,5-91,5]<\/td><\/tr><tr><td>XII. Autres tumeurs malignes<\/td><td>70<\/td><td>86,6<\/td><td>[75,8-92,8]<\/td><td>80,5<\/td><td>[68,9-88,2]<\/td><td>78,9<\/td><td>[67,0-86,9]<\/td><\/tr><tr><td>Total sans les Histiocytoses langheransiennes<\/td><td>29966<\/td><td>92,3<\/td><td>[92,0-92,6]<\/td><td>87,8<\/td><td>[87,4-88,2]<\/td><td>83,1<\/td><td>[82,6-83,5]<\/td><\/tr><tr><td>Histiocytoses langheransiennes<\/td><td>118<\/td><td>93,9<\/td><td>[87,7-97,1]<\/td><td>93,1<\/td><td>[86,6-96,5]<\/td><td>93,1<\/td><td>[86,6-96,5]<\/td><\/tr><tr><td>Total avec les Histiocytoses langheransiennes<\/td><td>30084<\/td><td>92,3<\/td><td>[92,0-92,6]<\/td><td>87,8<\/td><td>[87,4-88,2]<\/td><td>83,1<\/td><td>[82,7-83,5]<\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li>\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-up\"><\/i><\/span>\n\t\t<span class=\"accordion-title accordion-title\">\n\t\t\tEstimation du taux de survie \u00e0 5 ans des cancers de l'enfant en France m\u00e9tropolitaine, par groupe diagnostique et tranche d'\u00e2ge (2000-2016).\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-c6a9103\"><table><thead><th><\/th><th>< 1 an<\/th><th><\/th><th>1-4 ans<\/th><th><\/th><th>5-9 ans<\/th><th><\/th><th>10 -14 ans<\/th><th><\/th><th><\/th><\/thead><tbody><tr><td>Groupes et sous-groupes diagnostiques<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>I. Leuc\u00e9mies, syndromes my\u00e9loprolif\u00e9ratifs et my\u00e9lodysplasiques<\/td><td>61,2<\/td><td>[56,6-65,5]<\/td><td>89,9<\/td><td>[88,8-90,8]<\/td><td>89,2<\/td><td>[87,9-90,4]<\/td><td>80,8<\/td><td>[78,8-82,5]<\/td><td>**<\/td><\/tr><tr><td>I.a Leuc\u00e9mies lympho\u00efdes<\/td><td>53,8<\/td><td>[46,4-60,7]<\/td><td>93,8<\/td><td>[92,9-94,6]<\/td><td>91,4<\/td><td>[90,1-92,6]<\/td><td>84,0<\/td><td>[81,9-86]<\/td><td>**<\/td><\/tr><tr><td>I.b Leuc\u00e9mies aigu\u00ebs my\u00e9lo\u00efdes<\/td><td>66,1<\/td><td>[58,9-72,4]<\/td><td>66,9<\/td><td>[61,9-71,3]<\/td><td>80,8<\/td><td>[75,6-85,1]<\/td><td>67,6<\/td><td>[62,4-72,3]<\/td><td>**<\/td><\/tr><tr><td>II. Lymphomes et n\u00e9oplasmes r\u00e9ticulo-endoth\u00e9liaux<\/td><td>92,9<\/td><td>[59,1-99,0]<\/td><td>92,5<\/td><td>[89,3-94,8]<\/td><td>94,4<\/td><td>[92,7-95,7]<\/td><td>94,7<\/td><td>[93,5-95,6]<\/td><td><\/td><\/tr><tr><td>II.a Lymphomes de Hodgkin<\/td><td>-<\/td><td>-<\/td><td>100,0<\/td><td>-<\/td><td>98,6<\/td><td>[96,3-99,5]<\/td><td>97,4<\/td><td>[96,3-98,2]<\/td><td><\/td><\/tr><tr><td>II.b Lymphomes non hodgkiniens (sauf lymphomes de Burkitt)<\/td><td>90,9<\/td><td>[50,8-98,7]<\/td><td>86,4<\/td><td>[79,9-90,9]<\/td><td>89,9<\/td><td>[85,9-92,7]<\/td><td>90,3<\/td><td>[87,2-92,7]<\/td><td><\/td><\/tr><tr><td>II.c Lymphomes de Burkitt<\/td><td>100,0<\/td><td>-<\/td><td>96,0<\/td><td>[91,8-98,1]<\/td><td>95,1<\/td><td>[92,3-96,9]<\/td><td>90,4<\/td><td>[85,6-93,6]<\/td><td><\/td><\/tr><tr><td>III. Tumeurs du syst\u00e8me nerveux central et diverses tumeurs intracr\u00e2niennes et spinales<\/td><td>62,7<\/td><td>[58,2-66,9]<\/td><td>72,9<\/td><td>[71-74,6]<\/td><td>72,4<\/td><td>[70,6-74,2]<\/td><td>81,4<\/td><td>[79,7-83,1]<\/td><td>**<\/td><\/tr><tr><td>III.a \u00c9pendymomes et tumeurs du plexus choro\u00efde<\/td><td>70,5<\/td><td>[60,3-78,5]<\/td><td>67,9<\/td><td>[62,1-72,9]<\/td><td>79,9<\/td><td>[72,2-85,6]<\/td><td>86,9<\/td><td>[79,7-91,6]<\/td><td>**<\/td><\/tr><tr><td>III.b Astrocytomes<\/td><td>82,5<\/td><td>[75,1-87,8]<\/td><td>94,3<\/td><td>[92,6-95,5]<\/td><td>82,9<\/td><td>[80,3-85,3]<\/td><td>82,5<\/td><td>[79,4-85,1]<\/td><td>**<\/td><\/tr><tr><td>III.c Tumeurs embryonnaires du syst\u00e8me nerveux central<\/td><td>26,1<\/td><td>[18,7-34,1]<\/td><td>38,1<\/td><td>[33,8-42,3]<\/td><td>69,1<\/td><td>[64,6-73,1]<\/td><td>79,1<\/td><td>[73,3-83,8]<\/td><td>**<\/td><\/tr><tr><td>III.d Autres gliomes<\/td><td>67,2<\/td><td>[50,3-79,5]<\/td><td>44,5<\/td><td>[38,2-50,5]<\/td><td>26,2<\/td><td>[22,0-30,6]<\/td><td>47,0<\/td><td>[41,3-52,6]<\/td><td>**<\/td><\/tr><tr><td>III.e Autres tumeurs du syst\u00e8me nerveux central<\/td><td>84,2<\/td><td>[71,9-91,5]<\/td><td>94,2<\/td><td>[90,5-96,5]<\/td><td>95,6<\/td><td>[93,2-97,1]<\/td><td>96,7<\/td><td>[94,9-97,8]<\/td><td>**<\/td><\/tr><tr><td>IV. Tumeurs du syst\u00e8me nerveux sympathique<\/td><td>90,7<\/td><td>[88,6-92,4]<\/td><td>67,2<\/td><td>[64,3-70,0]<\/td><td>66,1<\/td><td>[59,7-71,8]<\/td><td>71,4<\/td><td>[60,0-80,0]<\/td><td>**<\/td><\/tr><tr><td>IV.a Neuroblastomes et ganglioneuroblastomes<\/td><td>90,7<\/td><td>[88,7-92,5]<\/td><td>67,1<\/td><td>[64,2-69,9]<\/td><td>66,2<\/td><td>[59,7-71,9]<\/td><td>62,8<\/td><td>[49,4-73,6]<\/td><td>**<\/td><\/tr><tr><td>V. R\u00e9tinoblastomes<\/td><td>99,5<\/td><td>[97,9-99,9]<\/td><td>99,0<\/td><td>[97,5-99,6]<\/td><td>100,0<\/td><td>-<\/td><td>100,0<\/td><td>-<\/td><td><\/td><\/tr><tr><td>VI. Tumeurs r\u00e9nales<\/td><td>88,3<\/td><td>[83,5-91,9]<\/td><td>94,3<\/td><td>[92,7-95,6]<\/td><td>93,2<\/td><td>[89,8-95,5]<\/td><td>81,9<\/td><td>[70,3-89,3]<\/td><td>**<\/td><\/tr><tr><td>VI.a N\u00e9phroblastomes et autres tumeurs non \u00e9pith\u00e9liales<\/td><td>88,3<\/td><td>[83,5-91,9]<\/td><td>94,3<\/td><td>[92,7-95,6]<\/td><td>93,3<\/td><td>[89,8-95,6]<\/td><td>85,0<\/td><td>[69,6-93,0]<\/td><td>**<\/td><\/tr><tr><td>VII. Tumeurs h\u00e9patiques<\/td><td>89,9<\/td><td>[80,8-94,8]<\/td><td>87,3<\/td><td>[80,8-91,7]<\/td><td>74,4<\/td><td>[55,0-86,4]<\/td><td>62,4<\/td><td>[45,5-75,4]<\/td><td>**<\/td><\/tr><tr><td>VII.a H\u00e9patoblastomes<\/td><td>89,7<\/td><td>[80,5-94,7]<\/td><td>87,5<\/td><td>[80,8-91,9]<\/td><td>74,6<\/td><td>[51,9-87,7]<\/td><td>44,4<\/td><td>[13,6-71,9]<\/td><td>**<\/td><\/tr><tr><td>VIII. Tumeurs malignes osseuses<\/td><td>85,7<\/td><td>[33,4-97,9]<\/td><td>74,2<\/td><td>[63,2-82,4]<\/td><td>75,2<\/td><td>[70,5-79,2]<\/td><td>73,6<\/td><td>[70,5-76,4]<\/td><td><\/td><\/tr><tr><td>VIII.a Ost\u00e9osarcomes<\/td><td>100,0<\/td><td>-<\/td><td>57,1<\/td><td>[28,4-78,0]<\/td><td>71,1<\/td><td>[63,4-77,4]<\/td><td>71,7<\/td><td>[67,2-75,7]<\/td><td><\/td><\/tr><tr><td>VIII.c Tumeurs d'Ewing<\/td><td>80,0<\/td><td>[20,4-96,9]<\/td><td>78,4<\/td><td>[65,6-86,9]<\/td><td>77,4<\/td><td>[70,7-82,7]<\/td><td>73,9<\/td><td>[68,9-78,2]<\/td><td><\/td><\/tr><tr><td>IX. Sarcomes des tissus mous et extra-osseux<\/td><td>69,8<\/td><td>[62,9-75,8]<\/td><td>75,2<\/td><td>[71,4-78,5]<\/td><td>75,3<\/td><td>[71,2-78,9]<\/td><td>68,2<\/td><td>[64,1-72,0]<\/td><td>**<\/td><\/tr><tr><td>IX.a Rhabdomyosarcomes<\/td><td>84,6<\/td><td>[73,3-91,4]<\/td><td>76,3<\/td><td>[71,9-80,0]<\/td><td>72,9<\/td><td>[67,5-77,6]<\/td><td>60,8<\/td><td>[53,1-67,6]<\/td><td>**<\/td><\/tr><tr><td>IX.b Fibrosarcomes, tumeurs des gaines des nerfs p\u00e9riph\u00e9riques et autres tumeurs fibreuses<\/td><td>88,7<\/td><td>[76,5-94,7]<\/td><td>91,7<\/td><td>[53,9-98,8]<\/td><td>82,6<\/td><td>[60,0-93,1]<\/td><td>67,2<\/td><td>[50,7-79,3]<\/td><td><\/td><\/tr><tr><td>IX.d Autres sarcomes des tissus mous<\/td><td>39,0<\/td><td>[26,7-51,1]<\/td><td>72,7<\/td><td>[63,0-80,3]<\/td><td>79,2<\/td><td>[71,3-85,2]<\/td><td>72,6<\/td><td>[66,8-77,6]<\/td><td>**<\/td><\/tr><tr><td>IX.e Sarcomes des tissus mous non pr\u00e9cis\u00e9s<\/td><td>56,3<\/td><td>[29,5-76,2]<\/td><td>49,7<\/td><td>[27,4-68,5]<\/td><td>74,5<\/td><td>[56,4-85,9]<\/td><td>71,0<\/td><td>[57,8-80,7]<\/td><td><\/td><\/tr><tr><td>X. Tumeurs germinales, trophoblastiques et gonadiques<\/td><td>91,3<\/td><td>[87,1-94,2]<\/td><td>96,3<\/td><td>[92,7-98,1]<\/td><td>96,9<\/td><td>[92,6-98,7]<\/td><td>93,5<\/td><td>[90,7-95,4]<\/td><td>*<\/td><\/tr><tr><td>X.a Tumeurs germinales du syst\u00e8me nerveux central<\/td><td>91,6<\/td><td>[76,1-97,2]<\/td><td>93,4<\/td><td>[84,8-97,2]<\/td><td>95,6<\/td><td>[88,6-98,3]<\/td><td>94,5<\/td><td>[90,3-96,9]<\/td><td><\/td><\/tr><tr><td>X.b Tumeurs germinales malignes extragonadiques et extracr\u00e2niennes<\/td><td>89,1<\/td><td>[83,5-92,9]<\/td><td>96,2<\/td><td>[88,6-98,8]<\/td><td>100,0<\/td><td>-<\/td><td>85,7<\/td><td>[66,1-94,4]<\/td><td><\/td><\/tr><tr><td>X.c Tumeurs germinales malignes gonadiques<\/td><td>100,0<\/td><td>-<\/td><td>100,0<\/td><td>-<\/td><td>100,0<\/td><td>-<\/td><td>96,0<\/td><td>[92,1-98,0]<\/td><td><\/td><\/tr><tr><td>XI. M\u00e9lanomes malins et autres tumeurs malignes \u00e9pith\u00e9liales<\/td><td>96,9<\/td><td>[79,8-99,6]<\/td><td>87,5<\/td><td>[79,0-92,7]<\/td><td>93,1<\/td><td>[88,6-95,8]<\/td><td>94,0<\/td><td>[91,8-95,6]<\/td><td><\/td><\/tr><tr><td>XI.b Carcinomes de la thyro\u00efde<\/td><td>100,0<\/td><td>-<\/td><td>100,0<\/td><td>-<\/td><td>98,8<\/td><td>[91,5-99,8]<\/td><td>98,9<\/td><td>[96,6-99,6]<\/td><td><\/td><\/tr><tr><td>XI.d M\u00e9lanomes malins<\/td><td>100,0<\/td><td>-<\/td><td>81,0<\/td><td>[62,5-91,0]<\/td><td>89,3<\/td><td>[76,2-95,4]<\/td><td>88,3<\/td><td>[79,9-93,4]<\/td><td><\/td><\/tr><tr><td>XII. Autres tumeurs malignes<\/td><td>100,0<\/td><td>-<\/td><td>76,5<\/td><td>[58,4-87,5]<\/td><td>85,7<\/td><td>[33,4-97,9]<\/td><td>58,6<\/td><td>[26,7-80,6]<\/td><td><\/td><\/tr><tr><td>Total sans les Histiocytoses langheransiennes<\/td><td>81,3<\/td><td>[79,9-82,7]<\/td><td>83,3<\/td><td>[82,6-84,1]<\/td><td>82,6<\/td><td>[81,7-83,4]<\/td><td>83,7<\/td><td>[82,9-84,5]<\/td><td>**<\/td><\/tr><tr><td>Histiocytoses langheransiennes<\/td><td>87,2<\/td><td>[73,8-94,1]<\/td><td>96,4<\/td><td>[86,2-99,1]<\/td><td>100,0<\/td><td>-<\/td><td>100,0<\/td><td>-<\/td><td><\/td><\/tr><tr><td>Total avec les Histiocytoses langheransiennes<\/td><td>81,4<\/td><td>[80,0-82,8]<\/td><td>83,4<\/td><td>[82,7-84,1]<\/td><td>82,6<\/td><td>[81,7-83,4]<\/td><td>83,8<\/td><td>[82,9-84,6]<\/td><td>**<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>** pvalue <0,01; * pvalue < 0,05<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li>\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-caret-up\"><\/i><\/span>\n\t\t<span class=\"accordion-title accordion-title accordion-title\">\n\t\t\tEvolution temporelle du taux de survie \u00e0 5 ans des cancers de l'enfant entre 2000 et 2016, estimation par groupe diagnostique et p\u00e9riode.\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-c6a9103\"><table><thead><th>Groupes et sous-groupes diagnostiques<\/th><th>2000-2004<\/th><th><\/th><th>2005-2009<\/th><th><\/th><th>2010-2016<\/th><th><\/th><th>p<\/th><\/thead><tbody><tr><td>I. Leuc\u00e9mies, syndromes my\u00e9loprolif\u00e9ratifs et my\u00e9lodysplasiques<\/td><td>83,00<\/td><td>[81,4-84,4]<\/td><td>87,00<\/td><td>[85,6-88,3]<\/td><td>87,60<\/td><td>[86,4-88,7]<\/td><td>**<\/td><\/tr><tr><td>I.a Leuc\u00e9mies lympho\u00efdes<\/td><td>89,20<\/td><td>[87,7-90,5]<\/td><td>91,00<\/td><td>[89,6-92,2]<\/td><td>89,90<\/td><td>[88,6-91,0]<\/td><td><\/td><\/tr><tr><td>I.b Leuc\u00e9mies aigu\u00ebs my\u00e9lo\u00efdes<\/td><td>59,40<\/td><td>[54,3-64,1]<\/td><td>71,40<\/td><td>[66,2-76,0]<\/td><td>78,20<\/td><td>[74,2-81,7]<\/td><td>**<\/td><\/tr><tr><td>II. Lymphomes et n\u00e9oplasmes r\u00e9ticulo-endoth\u00e9liaux<\/td><td>93,60<\/td><td>[91,8-94,9]<\/td><td>93,20<\/td><td>[91,4-94,7]<\/td><td>95,80<\/td><td>[94,6-96,8]<\/td><td>*<\/td><\/tr><tr><td>II.a Lymphomes de Hodgkin<\/td><td>96,70<\/td><td>[94,5-98,0]<\/td><td>96,70<\/td><td>[94,4-98,1]<\/td><td>99,30<\/td><td>[98,2-99,7]<\/td><td>**<\/td><\/tr><tr><td>II.b Lymphomes non hodgkiniens (sauf lymphomes de Burkitt)<\/td><td>91,20<\/td><td>[87,3-93,9]<\/td><td>86,60<\/td><td>[82,1-90,1]<\/td><td>90,50<\/td><td>[87,0-93,2]<\/td><td><\/td><\/tr><tr><td>II.c Lymphomes de Burkitt<\/td><td>91,40<\/td><td>[87,3-94,3]<\/td><td>95,20<\/td><td>[91,4-97,3]<\/td><td>95,40<\/td><td>[92,3-97,3]<\/td><td><\/td><\/tr><tr><td>III. Tumeurs du syst\u00e8me nerveux central et diverses tumeurs intracr\u00e2niennes et spinales<\/td><td>71,10<\/td><td>[69,1-73,0]<\/td><td>74,70<\/td><td>[72,8-76,5]<\/td><td>76,50<\/td><td>[75,0-78,0]<\/td><td>**<\/td><\/tr><tr><td>III.a \u00c9pendymomes et tumeurs du plexus choro\u00efde<\/td><td>62,50<\/td><td>[55,3-68,9]<\/td><td>77,60<\/td><td>[71,2-82,8]<\/td><td>80,80<\/td><td>[75,3-85,1]<\/td><td>**<\/td><\/tr><tr><td>III.b Astrocytomes<\/td><td>86,90<\/td><td>[84,4-89,1]<\/td><td>88,10<\/td><td>[85,5-90,2]<\/td><td>86,40<\/td><td>[84,3-88,2]<\/td><td><\/td><\/tr><tr><td>III.c Tumeurs embryonnaires du syst\u00e8me nerveux central<\/td><td>52,20<\/td><td>[47,3-56,9]<\/td><td>55,40<\/td><td>[50,4-60,1]<\/td><td>59,00<\/td><td>[54,6-63,1]<\/td><td><\/td><\/tr><tr><td>III.d Autres gliomes<\/td><td>35,80<\/td><td>[30,2-41,5]<\/td><td>39,50<\/td><td>[34,0-44,9]<\/td><td>40,20<\/td><td>[35,4-45,0]<\/td><td><\/td><\/tr><tr><td>III.e Autres tumeurs du syst\u00e8me nerveux central<\/td><td>93,80<\/td><td>[90,6-95,9]<\/td><td>95,80<\/td><td>[93,3-97,4]<\/td><td>95,70<\/td><td>[93,7-97,1]<\/td><td><\/td><\/tr><tr><td>IV. Tumeurs du syst\u00e8me nerveux sympathique<\/td><td>72,70<\/td><td>[69,3-75,8]<\/td><td>75,30<\/td><td>[72,0-78,3]<\/td><td>80,30<\/td><td>[77,5-82,9]<\/td><td>**<\/td><\/tr><tr><td>IV.a Neuroblastomes et ganglioneuroblastomes<\/td><td>72,50<\/td><td>[69,1-75,7]<\/td><td>75,20<\/td><td>[71,8-78,2]<\/td><td>80,10<\/td><td>[77,2-82,7]<\/td><td>**<\/td><\/tr><tr><td>V. R\u00e9tinoblastomes<\/td><td>99,20<\/td><td>[96,8-99,8]<\/td><td>98,50<\/td><td>[96,0-99,4]<\/td><td>100,00<\/td><td>-<\/td><td><\/td><\/tr><tr><td>VI. Tumeurs r\u00e9nales<\/td><td>91,60<\/td><td>[88,7-93,7]<\/td><td>92,90<\/td><td>[90,3-94,9]<\/td><td>93,30<\/td><td>[91,0-95,0]<\/td><td><\/td><\/tr><tr><td>VI.a N\u00e9phroblastomes et autres tumeurs non \u00e9pith\u00e9liales<\/td><td>92,00<\/td><td>[89,1-94,2]<\/td><td>92,90<\/td><td>[90,3-94,9]<\/td><td>93,70<\/td><td>[91,4-95,4]<\/td><td><\/td><\/tr><tr><td>VII. Tumeurs h\u00e9patiques<\/td><td>83,10<\/td><td>[72,2-90,0]<\/td><td>78,30<\/td><td>[68,7-85,3]<\/td><td>87,00<\/td><td>[79,8-91,7]<\/td><td><\/td><\/tr><tr><td>VII.a H\u00e9patoblastomes<\/td><td>86,90<\/td><td>[75,5-93,2]<\/td><td>82,00<\/td><td>[71,6-88,9]<\/td><td>87,10<\/td><td>[79,5-92,0]<\/td><td><\/td><\/tr><tr><td>VIII. Tumeurs malignes osseuses<\/td><td>74,60<\/td><td>[70,0-78,5]<\/td><td>75,20<\/td><td>[70,7-79,1]<\/td><td>73,10<\/td><td>[68,9-76,8]<\/td><td><\/td><\/tr><tr><td>VIII.a Ost\u00e9osarcomes<\/td><td>73,10<\/td><td>[66,3-78,7]<\/td><td>74,10<\/td><td>[66,9-79,9]<\/td><td>68,00<\/td><td>[61,5-73,6]<\/td><td><\/td><\/tr><tr><td>VIII.c Tumeurs d'Ewing<\/td><td>74,70<\/td><td>[67,4-80,6]<\/td><td>74,10<\/td><td>[67,4-79,7]<\/td><td>77,00<\/td><td>[71,1-81,9]<\/td><td><\/td><\/tr><tr><td>IX. Sarcomes des tissus mous et extra-osseux<\/td><td>69,00<\/td><td>[64,8-72,7]<\/td><td>73,50<\/td><td>[69,7-77,0]<\/td><td>74,80<\/td><td>[71,4-77,8]<\/td><td><\/td><\/tr><tr><td>IX.a Rhabdomyosarcomes<\/td><td>67,40<\/td><td>[61,6-72,4]<\/td><td>74,30<\/td><td>[69,0-78,8]<\/td><td>76,60<\/td><td>[71,9-80,5]<\/td><td><\/td><\/tr><tr><td>IX.b Fibrosarcomes, tumeurs des gaines des nerfs p\u00e9riph\u00e9riques et autres tumeurs fibreuses<\/td><td>74,40<\/td><td>[57,6-85,3]<\/td><td>80,00<\/td><td>[64,0-89,5]<\/td><td>87,90<\/td><td>[76,1-94,0]<\/td><td><\/td><\/tr><tr><td>IX.d Autres sarcomes des tissus mous<\/td><td>72,10<\/td><td>[64,6-78,3]<\/td><td>71,30<\/td><td>[63,9-77,4]<\/td><td>69,60<\/td><td>[62,9-75,2]<\/td><td><\/td><\/tr><tr><td>IX.e Sarcomes des tissus mous non pr\u00e9cis\u00e9s<\/td><td>60,00<\/td><td>[43,2-73,3]<\/td><td>70,70<\/td><td>[54,3-82,2]<\/td><td>70,30<\/td><td>[56,4-80,5]<\/td><td><\/td><\/tr><tr><td>X. Tumeurs germinales, trophoblastiques et gonadiques<\/td><td>92,30<\/td><td>[88,9-94,7]<\/td><td>93,10<\/td><td>[89,8-95,3]<\/td><td>96,50<\/td><td>[94,3-97,9]<\/td><td><\/td><\/tr><tr><td>X.a Tumeurs germinales du syst\u00e8me nerveux central<\/td><td>91,80<\/td><td>[85,3-95,5]<\/td><td>94,00<\/td><td>[87,9-97,1]<\/td><td>96,50<\/td><td>[92,4-98,4]<\/td><td><\/td><\/tr><tr><td>X.b Tumeurs germinales malignes extragonadiques et extracr\u00e2niennes<\/td><td>92,20<\/td><td>[84,4-96,2]<\/td><td>85,10<\/td><td>[76,2-90,9]<\/td><td>95,30<\/td><td>[89,1-98,0]<\/td><td>*<\/td><\/tr><tr><td>X.c Tumeurs germinales malignes gonadiques<\/td><td>95,70<\/td><td>[90,0-98,2]<\/td><td>98,30<\/td><td>[93,2-99,6]<\/td><td>99,20<\/td><td>[94,7-99,9]<\/td><td><\/td><\/tr><tr><td>XI. M\u00e9lanomes malins et autres tumeurs malignes \u00e9pith\u00e9liales<\/td><td>92,80<\/td><td>[89-95,4]<\/td><td>93,30<\/td><td>[89,6-95,7]<\/td><td>93,30<\/td><td>[90,5-95,4]<\/td><td><\/td><\/tr><tr><td>XI.b Carcinomes de la thyro\u00efde<\/td><td>98,20<\/td><td>[93,0-99,5]<\/td><td>100,00<\/td><td>-<\/td><td>98,50<\/td><td>[93,9-99,6]<\/td><td><\/td><\/tr><tr><td>XI.d M\u00e9lanomes malins<\/td><td>84,10<\/td><td>[71,6-91,4]<\/td><td>87,20<\/td><td>[73,6-94,0]<\/td><td>90,20<\/td><td>[80,3-95,3]<\/td><td><\/td><\/tr><tr><td>XII. Autres tumeurs malignes<\/td><td>57,10<\/td><td>[28,4-78,0]<\/td><td>90,00<\/td><td>[65,6-97,4]<\/td><td>81,80<\/td><td>[63,9-91,4]<\/td><td><\/td><\/tr><tr><td>Total sans les Histiocytoses langheransiennes<\/td><td>80,80<\/td><td>[79,9-81,6]<\/td><td>83,30<\/td><td>[82,5-84,1]<\/td><td>84,60<\/td><td>[83,9-85,2]<\/td><td>**<\/td><\/tr><tr><td>Histiocytoses langheransiennes<\/td><td>94,30<\/td><td>[79,0-98,5]<\/td><td>97,10<\/td><td>[80,9-99,6]<\/td><td>89,10<\/td><td>[75,7-95,3]<\/td><td><\/td><\/tr><tr><td>Total avec les Histiocytoses langheransiennes<\/td><td>80,80<\/td><td>[80,0-81,7]<\/td><td>83,30<\/td><td>[82,5-84,1]<\/td><td>84,60<\/td><td>[83,9-85,3]<\/td><td>**<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>** pvalue <0,01; * pvalue < 0,05<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li><\/ul><\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Nombre de cas annuel moyen (N), taux d&#8217;incidence annuel brut, standardis\u00e9 et cumul\u00e9 \u00e0 18 ans en cas par million, et sex-ratio des cancers de l&#8217;enfant en France m\u00e9tropolitaine (2014-2020*) N_annuelBrutStandardisecumuleSex_ratio I. Leuc\u00e9mies, syndromes my\u00e9loprolif\u00e9ratifs et my\u00e9lodysplasiques 579 41,2 42,3 777,6 1,2 I.a Leuc\u00e9mies lympho\u00efdes 447 31,8 32,6 597,5 1,3 I.b Leuc\u00e9mies aigu\u00ebs my\u00e9lo\u00efdes 90 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":3281,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-3331","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/pages\/3331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=3331"}],"version-history":[{"count":1,"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/pages\/3331\/revisions"}],"predecessor-version":[{"id":5519,"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/pages\/3331\/revisions\/5519"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/media\/3281"}],"wp:attachment":[{"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=3331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}